BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13

On February 6, 2018 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, reported that its Chief Executive Officer, Philip Serlin, will present a company update at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:30 am EST (Press release, BioLineRx, FEB 6, 2018, View Source;p=RssLanding&cat=news&id=2330476 [SID1234523741]). The conference will be held at the New York Marriott Marquis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on BioLineRx’s website. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

Investors or potential partners attending the conference who wish to meet with BioLineRx management should contact the BIO Partnering Team at [email protected].

Leap Therapeutics to Present at the 20th Annual BIO CEO & Investor Conference

On February 6, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, Chief Financial Officer, will present a corporate overview at the 20TH Annual BIO CEO & Investor Conference being held at the New York Marriott Marquis in New York City on February 12-13, 2018 (Press release, Leap Therapeutics, FEB 6, 2018, View Source;p=RssLanding&cat=news&id=2330482 [SID1234523761]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

20TH Annual BIO CEO & Investor Conference – Leap Presentation Details:
Date: Tuesday, February 13, 2018
Time: 1:45 P.M. Eastern Time

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at www.investors.leaptx.com, where a replay of the event will also be available for a limited time.

Varian Halcyon Treatment System Receives AERB Certificate for Import & Supply in India

On February 6, 2018 Varian (NYSE: VAR) reported the Halcyon cancer treatment platform has received Atomic Energy Regulatory Board (AERB) Certificate for Import and Supply in India (Press release, Varian Medical Systems, FEB 6, 2018, View Source [SID1234523896]). This registration allows Varian to now market this new system in India. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), and is well suited to treat a majority of cancer patients, offering advanced treatments for prostate, breast, head & neck, and many other forms of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With AERB No Objection Certificate, clinicians in India now have access to Halcyon, which is engineered to revolutionize the clinical workflow and could help advance cost-effective cancer care across the country," said Ashok Kakkar, senior managing director, Varian India. "We look forward to continuing our close collaboration with clinical partners across India and helping realize a world without fear of cancer."

Halcyon is an advanced system that was designed to improve patient comfort, simplify operations, and shorten the time from installation to first-treatment without sacrificing quality. Its quiet operating environment, which is up to 2x quieter than other systems, has been designed with the patients in mind. Additionally, Halcyon has a low couch height for easy patient access, and soft indirect ambient lighting in the gantry opening.

Featuring a 100cm gantry opening, which is larger than those on standard CT machines, Halcyon is capable of rotations 4x faster than c-arm gantries for rapid imaging and treatment. The system is also capable of fast and sharp volumetric imaging in as little as 15 seconds. With Halcyon treatments, a complex image guided IMRT plan is clinically accelerated compared to those delivered on traditional devices.

Operationally, Halcyon features a streamlined workflow that only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies. To assist in the reduction of time and construction costs from installation to first patient treatment, Halcyon comes pre-commissioned, requires less shielding than traditional systems, can fit in a vault as small as 5.9 meters (19.68 feet) x 5.539 meters (18.17 feet) x 2.743 meters (8.99 feet) high and can be installed in two weeks or less.

For more information on Halcyon visit www.varian.com/halcyon.

Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

On February 6, 2018 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, reported that the Company will present at the 2018 BIO CEO Investor Conference being held February 12 & 13, 2018 at the New York Marriott Marquis, New York (Press release, Cyclacel, FEB 6, 2018, View Source [SID1234523742]). Spiro Rombotis, President & Chief Executive Officer will provide an overview of the Company and its progress in key programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Information on the presentation is as follows:

Event: 2018 BIO CEO Investor Conference
Date: Monday, February 12, 2018
Time: 10:45 am ET
Location: Odets Room, New York Marriott Marquis
A live webcast of the presentation will be available through the Company’s website: www.cyclacel.com. The webcast will be archived for 90 days.

MacroGenics to Participate in Two Upcoming Investor Conferences

On February 6, 2018 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in two upcoming investor conferences (Press release, MacroGenics, FEB 6, 2018, View Source [SID1234523762]). These two conferences include:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SunTrust Robinson Humphrey 2018 Orphan Drug Day — Management will participate in the conference on Tuesday, February 13, 2018, at the JW Marriott Essex House in New York.

Leerink Partners 7th Annual Global Healthcare Conference — Scott Koenig, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, February 15, 2018 at 10:30 am ET at the Lotte New York Palace in New York.

A webcast of the Leerink conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.